Cargando…
KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
KRAS is the most frequently mutated oncogene identified in human cancers. Despite the numerous efforts to develop effective specific inhibitors against KRAS, this molecule has remained “undruggable” for decades. The development of direct KRAS inhibitors, such as sotorasib, the first FDA-approved dru...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408881/ https://www.ncbi.nlm.nih.gov/pubmed/36012655 http://dx.doi.org/10.3390/ijms23169391 |